Amany R Keruakous
Overview
Explore the profile of Amany R Keruakous including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keruakous A, Walker L, Denlinger M, Mian M, Bradshaw D, Kota V, et al.
Hematol Rep
. 2024 Jul;
16(3):479-486.
PMID: 39051419
High-dose chemotherapy (HD-CHT) followed by autologous stem cell transplantation (ASCT) remains the gold standard for eligible multiple myeloma (MM) patients, even amidst evolving therapeutic options. Clinical trials have demonstrated ASCT's...
2.
Brown Z, Scott C, Zhang L, Sadek R, Clarke A, Jillella A, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jun;
24(9):642-647.
PMID: 38845275
Background: No standard criteria for dose reduction exists for high-dose melphalan for autologous stem cell transplantation (ASCT) for multiple myeloma (MM) due to limited and conflicting evidence. Objective: To evaluate...
3.
Keruakous A, Akpan I, Chahin M, Kirolos A, Keruakous M
Front Public Health
. 2024 May;
12:1381075.
PMID: 38756877
This research delves into the disparities in access to oncology care among cancer patients in Georgia, with a specific focus on the distinct challenges faced by African American (AA) individuals...
4.
Keruakous A, Soror N, Jimenez S, Ashley R, Keruakous M, Sadek B
Front Public Health
. 2023 Mar;
11:1100466.
PMID: 36935668
No abstract available.
5.
Keruakous A, Holter-Chakrabarty J, Schmidt S, Khawandanah M, Selby G, Yuen C
Hematol Oncol Stem Cell Ther
. 2023 Jan;
16(1):52-60.
PMID: 36634281
Objective/background: Allogeneic hematopoietic stem cell transplant (HSCT) is the potential curative modality for poor-risk acute myeloid leukemia (AML), relapse remains the main reason for transplant failure. Early-phase studies showed azacitidine...
6.
Chahin M, Branham Z, Fox A, Leurinda C, Keruakous A
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565407
Multiple myeloma is a relatively common clonal plasma cell disorder, comprising 17% of hematologic malignancies. One of the hallmark features of this disease is immunoparesis, which is characterized by the...
7.
Keruakous A, Asch A, Aljumaily R, Zhao D, Yuen C
Transpl Immunol
. 2022 Jan;
71:101544.
PMID: 35093506
Introduction: Natural killer cells are a potent effector lymphocyte subset that can induce cytotoxicity without the need for antigen sensitization or presentation. NK cells are a tempting target -for immune...
8.
Keruakous A, Day S, Garcia-Ramiu K, Yarbrough M, Asch A
Cureus
. 2021 Sep;
13(8):e17202.
PMID: 34540430
Background Clinical trials are key elements of the processes that account for many of the recent advances in cancer care. Unfortunately, they are becoming more challenging to conduct. Furthermore, a...
9.
Keruakous A, Balakrishna P, Schmidt S, Autry M, Asch A
Ann Hematol
. 2021 Jan;
100(6):1629-1630.
PMID: 33433650
No abstract available.
10.
Sadek B, Homayounfar G, Abi Raad R, Niemierko A, Shenouda M, Keruakous A, et al.
Breast Cancer Res Treat
. 2015 Oct;
154(1):71-9.
PMID: 26420403
To determine rates of loco-regional recurrence (LRR), distant failure and overall survival for patients with breast cancer treated with breast-conserving therapy (BCT) with a close or positive surgical margin (C/PM)...